Stock Screener App

無料 - Play StoreApp Store

インストールインストール

Dow:

Nasdaq:

S&P 500:

SYRE

$96.562.43%-2.40

Spyre Therapeutics Inc (SYRE)

Date: O: H: L: C: Vol:

Spyre Therapeutics Inc (SYRE) 最新ニュース

symbol__ Stock Quote Price and Forecast - CNN

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 - GlobeNewswire Inc.

Mouse studies found combinations of experimental bowel treatments worked better - Stock Titan

Spyre Therapeutics grants equity inducement awards to employee - scanx.trade

UBS Initiates Spyre Therapeutics at Buy With $120 Price Target - Yahoo Finance

Spyre Therapeutics Announces Major Equity Financing Agreement - The Globe and Mail

Spyre Therapeutics Launches $350 Million Stock Offering Underwritten by Jefferies, TD, Leerink, Stifel - TradingView

Spyre Therapeutics launches public stock offering By Investing.com - Investing.com South Africa

Spyre Therapeutics Prices $350 Million Public Offering of Common Stock - Quiver Quantitative

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock - GlobeNewswire Inc.

Spyre Therapeutics stock falls on public offering launch - Yahoo Finance

Spyre Therapeutics launches public stock offering - Investing.com

A proposed stock sale could help Spyre advance a new drug program into late-stage development. - Stock Titan

Spyre Therapeutics prices $350M stock offering at $85/share - Investing.com

Form 4 Spyre Therapeutics Inc For: 2 October By Investing.com - Investing.com Nigeria

After exercising $14.50 options, Spyre Therapeutics (SYRE) CFO sells 25,000 shares. - Stock Titan

Spyre Therapeutics CEO Cameron Turtle sells $1.38m in SYRE stock - Investing.com

After exercising $14.50 options, Spyre Therapeutics (SYRE) legal chief sells 28,933 shares. - Stock Titan

Spyre Therapeutics CFO Scott Burrows sells $2.26m in stock - Investing.com

Two new hires get Spyre stock awards that vest over time - Stock Titan

After a $2.44M September sale, an officer proposes selling more Spyre Therapeutics (SYRE) shares. - Stock Titan

45,000 shares are proposed for sale at Spyre Therapeutics (SYRE), following two earlier sales. - Stock Titan

Spyre draws new Overweight at J.P. Morgan on IBD potential - Seeking Alpha

A 17,500-share sale is proposed by Spyre Therapeutics (Nasdaq: SYRE) officer Scott Burrows. - Stock Titan

Spyre Therapeutics, Inc. (SYRE) Stock Price, News, Quote & History - Yahoo! Finance Canada

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It? - Yahoo Finance

Spyre Therapeutics at Wells Fargo conference: betting on combination biologics - Investing.com Canada

Transcript : Spyre Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com

Spyre Therapeutics at Citi summit: bets on autoimmune combinations By Investing.com - Investing.com Canada

Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study - The Globe and Mail

Spyre Therapeutics Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus

Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study - Yahoo Finance

Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com South Africa

Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com Nigeria

Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com Canada

Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com India

Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com UK

SYRE Reiterated by Wedbush -- Maintained Price Target at $123 - GuruFocus

Baird reiterates Spyre stock Outperform rating on positive trial data By Investing.com - Investing.com India

Baird reiterates Spyre stock Outperform rating on positive trial data By Investing.com - Investing.com Canada

SYRE Reiterated by BTIG -- Price Target Maintained at $121 - GuruFocus

Spyre Therapeutics (SYRE) Reports Positive Phase 2 SKYLINE Trial Results Amid High Valuation Concerns - GuruFocus

Spyre reports positive ulcerative colitis trial data for SPY003 By Investing.com - Investing.com Canada

Spyre reports positive ulcerative colitis trial data for SPY003 By Investing.com - Investing.com India

Spyre reports positive ulcerative colitis trial data for SPY003 - Investing.com

An experimental ulcerative colitis treatment cut a disease score by 10 points - Stock Titan

Spyre posts positive Phase 2 SKYLINE Part A: SPY003 cuts RHI 10.0 pts; Part B enrolling, topline in 2027 - TradingView

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations - Yahoo Finance

Spyre Therapeutics Announces Grants of Inducement Awards - manilatimes.net

Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing - marketscreener.com

SYREに類似

CORT$81.125.62%

CYTK$62.990.51%

TGTX$61.185.34%

PTGX$144.850.35%

ARWR$59.900.98%